ARMATA PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ARMATA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 163.02K shares.
- ARMATA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 201.71K shares.
- ARMATA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-12-31 was 0.00 shares.
- ARMATA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-09-30 was 0.00 shares.
- ARMATA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 201.60K shares, a 440.75% increase from fiscal 2024.
- ARMATA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 37.28K shares, a 2385.47% increase from fiscal 2023.
- ARMATA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 1.50K shares, a 96.08% decline from fiscal 2022.
- ARMATA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 38.29K shares, a 61.53% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 163.02K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | |
| 2026-03-31 | 201.71K shares 10-Q · filed 2026-05-13 | |
| 2025-12-31 | 201.60K shares 10-K · filed 2026-03-25 | |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | 37.28K shares 10-K · filed 2025-03-21 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 37.28K shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | 23.88K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | |
| 2024-03-31 | 13.41K shares 10-Q · filed 2024-05-07 | |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | 1.50K shares 10-K · filed 2024-03-21 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | 38.29K shares 10-K · filed 2023-03-16 |
| 2022-09-30 | 16.51K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | |
| 2021-12-31 | 26.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | 99.52K shares 10-K · filed 2022-03-17 |
| 2021-09-30 | 27.38K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 73.52K shares derived: sum of 4 quarters · filed 2021-11-10 |
| 2021-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | |
| 2021-03-31 | 46.13K shares 10-Q · filed 2021-05-13 | |
| 2020-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | 27.38K shares 10-K · filed 2021-03-18 |
| 2015-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-27 | 214.81K shares 10-K · filed 2017-03-27 |
| 2015-09-30 | 294.81K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |